MAPS, Eight Capital And Integrated V.C. Backs Numinus $6M Offering
MAPS, Eight Capital And Integrated V.C. Backs Numinus $6M Offering
The TDR Three Takeaways:
TDR 三點要點：
- Numinus Wellness Inc. partners with Eight Capital in a $6 million bought deal, involving the purchase of 50,000,000 units, strengthening the company's financial position for future mental health initiatives.
- The involvement of MAPS and Integrated V.C. in Numinus's offering highlights growing interest and confidence in the field of psychedelic-assisted therapy, particularly for mental health care advancements.
- The Numinus offering structure, including common shares and warrants with an Over-Allotment Option, indicates a strategic approach to funding and expanding Numinus's capabilities in mental health care and therapist training programs.
- Numinus Wellness Inc.與Eight Capital合作達成了600萬美元的收購協議，涉及購買5000萬個單位，從而鞏固了該公司未來心理健康計劃的財務狀況。
- MAPS和Integrated V.C. 參與Numinus的產品凸顯了人們對迷幻輔助療法領域的興趣和信心與日俱增，尤其是對心理衛生保健進步的興趣和信心。
- Numinus的發行結構，包括普通股和帶有超額配股權的認股權證，表明了爲Numinus提供資金和擴大其在心理保健和治療師培訓計劃方面的能力的戰略方針。
Numinus Wellness Inc. (TSX:NUMI) entered into an agreement with Eight Capital. This agreement involves a bought deal public offering where Eight Capital and a syndicate of underwriters, including Stifel GMP, will purchase 50,000,000 units at $0.12 each, totaling $6 million.
Numinus Wellness Inc.（多倫多證券交易所股票代碼：NUMI）與Eight Capital簽訂了協議。該協議涉及一項收購交易，其中Eight Capital和包括Stifel GMP在內的承銷商集團將以每股0.12澳元的價格購買5000萬個單位，總額爲600萬美元。
The units in this offering are composed of one common share and one warrant. Each warrant allows purchase of one common share at $0.18, valid for 24 months after the offering's closure. Additionally, Eight Capital has an Over-Allotment Option to buy up to 15% more units at the offering price, potentially raising an extra $900,000 within 30 days after the closing date, set for approximately February 7, 2024.
本次發行的單位由一股普通股和一份認股權證組成。每份認股權證允許以0.18美元的價格購買一股普通股，在發行結束後的24個月內有效。此外，Eight Capital擁有超額配股權，可以按發行價格再購買最多15％的單位，有可能在截止日期（定於2024年2月7日左右）後的30天內額外籌集90萬美元。
Lead orders for the offering come from Integrated V.C., a venture fund, and the Multidisciplinary Association for Psychedelic Studies (MAPS). Numinus CEO, Payton Nyquvest, states that the funds will support the company's mental health initiatives. MAPS's support, as noted by its founder Rick Doblin, Ph.D., includes a focus on therapist training in psychedelic-assisted therapy, particularly experiential training.
此次發行的主要訂單來自風險基金綜合風險投資公司和迷幻研究多學科協會（MAPS）。Numinus首席執行官Payton Nyquvest表示，這筆資金將支持該公司的心理健康計劃。正如其創始人裏克·多布林博士所指出的那樣，MAPS的支持包括將重點放在迷幻輔助療法的治療師培訓上，尤其是體驗式訓練。
The Numinus offering will be conducted through a prospectus supplement to the company's base shelf prospectus dated June 27, 2023. It will be available in Canada (excluding Quebec) and may also be offered in the United States and other offshore jurisdictions through private placements. This is subject to regulatory and stock exchange approvals, including from the Toronto Stock Exchange (TSX).
Numinus的發行將通過公司2023年6月27日基本架構招股說明書的補充招股說明書進行發行。它將在加拿大（不包括魁北克）上市，也可能通過私募在美國和其他離岸司法管轄區發行。這需要獲得監管機構和證券交易所的批准，包括多倫多證券交易所（TSX）的批准。
This move by Numinus Wellness Inc. indicates a strategic effort to expand its mental health care offerings, particularly in psychedelic-assisted therapies. The involvement of healthcare investors and researchers like MAPS suggests a growing interest and confidence in this field.
Numinus Wellness Inc.的這一舉動表明了擴大其心理保健服務的戰略舉措，特別是在迷幻輔助療法方面。醫療保健投資者和像MAPS這樣的研究人員的參與表明，人們對該領域的興趣和信心與日俱增。
譯文內容由第三人軟體翻譯。